| Range: | 0.59-2.12 | Vol Avg: | 41053 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | -0.38 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed May 03 2000 | Empoloyees: | 8 | ||
| CUSIP: | 550241103 | CIK: | 0000922247 | ISIN: | US23254X2018 | Country: | US |
| CEO: | Mr. N. Scott Fine | Website: | https://www.cyclotherapeutics.com | ||||
CYTH 0.68 Stock Price Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow